References: Systemic lupus erythematosus (SLE) in children and adolescents

  • Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Annals of the Rheumatic Diseases 2017;76(11):1788-96. https://www.ncbi.nlm.nih.gov/pubmed/28630236
  • Huang X, Jia N, Xiao F, Sun C, Zhu J, Lai J, et al. Differences in the Clinical Manifestations and Mortality of Systemic Lupus Erythematosus Onset in Children and Adults: A Systematic Review and Meta-Analysis. International Archives of Allergy and Immunology 2022;183(1):116-26. https://www.ncbi.nlm.nih.gov/pubmed/34818238
  • Mackie FE, Kainer G, Adib N, Boros C, Elliott EJ, Fahy R, et al. The national incidence and clinical picture of SLE in children in Australia - a report from the Australian Paediatric Surveillance Unit. Lupus 2015;24(1):66-73. https://www.ncbi.nlm.nih.gov/pubmed/25288030
  • Massias JS, Smith EMD, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus 2020;29(5):474-81. https://www.ncbi.nlm.nih.gov/pubmed/32233733
  • Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs 2021;23(4):331-47. https://www.ncbi.nlm.nih.gov/pubmed/34244988
  • Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus 2015;24(1):10-7. https://www.ncbi.nlm.nih.gov/pubmed/25117653